Advertisement
Journal of Clinical Oncology  
Search for:
Limit by:
  Browse by Subject or Issue
Home Search or Browse JCO Subscriptions PDA Services My JCO Customer Service

Originally published as JCO Early Release 10.1200/JCO.2006.06.4451 on May 8 2006

Journal of Clinical Oncology, Vol 24, No 19 (July 1), 2006: pp. 3187-3205
© 2006 American Society of Clinical Oncology.

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Save to my personal folders
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Smith, T. J.
Right arrow Articles by Wolff, A. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Smith, T. J.
Right arrow Articles by Wolff, A. C.
Related Articles
Right arrowRelated Editorial
Right arrowRelated Correspondence

ASCO SPECIAL ARTICLE

2006 Update of Recommendations for the Use of White Blood Cell Growth Factors: An Evidence-Based Clinical Practice Guideline

Thomas J. Smith, (Chair), James Khatcheressian, Gary H. Lyman, Howard Ozer, James O. Armitage, Lodovico Balducci, Charles L. Bennett, Scott B. Cantor, Jeffrey Crawford, Scott J. Cross, George Demetri, Christopher E. Desch, Philip A. Pizzo, Charles A. Schiffer, Lee Schwartzberg, Mark R. Somerfield, George Somlo, James C. Wade, James L. Wade, Rodger J. Winn, Antoinette J. Wozniak, Antonio C. Wolff

From the American Society of Clinical Oncology, Alexandria, VA

Address reprint requests to American Society of Clinical Oncology, Cancer Policy and Clinical Affairs, 1900 Duke Street, Suite 200, Alexandria, VA 22314; e-mail: guidelines{at}asco.org

PURPOSE: To update the 2000 American Society of Clinical Oncology guideline on the use of hematopoietic colony-stimulating factors (CSF).

UPDATE METHODOLOGY: The Update Committee completed a review and analysis of pertinent data published from 1999 through September 2005. Guided by the 1996 ASCO clinical outcomes criteria, the Update Committee formulated recommendations based on improvements in survival, quality of life, toxicity reduction and cost-effectiveness.

RECOMMENDATIONS: The 2005 Update Committee agreed unanimously that reduction in febrile neutropenia (FN) is an important clinical outcome that justifies the use of CSFs, regardless of impact on other factors, when the risk of FN is approximately 20% and no other equally effective regimen that does not require CSFs is available. Primary prophylaxis is recommended for the prevention of FN in patients who are at high risk based on age, medical history, disease characteristics, and myelotoxicity of the chemotherapy regimen. CSF use allows a modest to moderate increase in dose-density and/or dose-intensity of chemotherapy regimens. Dose-dense regimens should only be used within an appropriately designed clinical trial or if supported by convincing efficacy data. Prophylactic CSF for patients with diffuse aggressive lymphoma aged 65 years and older treated with curative chemotherapy (CHOP or more aggressive regimens) should be given to reduce the incidence of FN and infections. Current recommendations for the management of patients exposed to lethal doses of total body radiotherapy, but not doses high enough to lead to certain death due to injury to other organs, includes the prompt administration of CSF or pegylated G-CSF.

Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.


Related Editorial

  • When the Risk of Febrile Neutropenia Is 20%, Prophylactic Colony-Stimulating Factor Use Is Clinically Effective, but Is It Cost-Effective?
    Jared R. Adams, Cara Angelotta, and Charles L. Bennett
    JCO 2006 24: 2975-2977 [Full Text]

Related Correspondence

  • Can the Addition of Prophylactic Filgrastim Be Considered Cost Effective in Early Breast Cancer Patients Treated With Epirubicin and Cyclophosphamide?
    Gianluigi Ferretti and Paola Papaldo
    JCO 2006 24: 5615-5616 [Full Text]


This article has been cited by other articles:


Home page
Clin. Cancer Res.Home page
R. B. Klisovic, W. Blum, X. Wei, S. Liu, Z. Liu, Z. Xie, T. Vukosavljevic, C. Kefauver, L. Huynh, J. Pang, et al.
Phase I Study of GTI-2040, an Antisense to Ribonucleotide Reductase, in Combination with High-Dose Cytarabine in Patients with Acute Myeloid Leukemia
Clin. Cancer Res., June 15, 2008; 14(12): 3889 - 3895.
[Abstract] [Full Text] [PDF]


Home page
JAMAHome page
S. E. Harrington and T. J. Smith
The Role of Chemotherapy at the End of Life: "When Is Enough, Enough?"
JAMA, June 11, 2008; 299(22): 2667 - 2678.
[Abstract] [Full Text] [PDF]


Home page
Am J Health Syst PharmHome page
S. Y. Barbour
Caring for the treatment-experienced breast cancer patient: The pharmacist's role
Am. J. Health Syst. Pharm., May 15, 2008; 65(10_Supplement_3): S16 - S22.
[Abstract] [Full Text] [PDF]


Home page
J Oncol PractHome page
G. H. Lyman
Undertreatment of Cancer Patients With Chemotherapy Is a Global Concern
J. Oncol. Pract, May 1, 2008; 4(3): 114 - 115.
[Full Text] [PDF]


Home page
Ann OncolHome page
D. Weycker, J. Malin, J. Edelsberg, A. Glass, M. Gokhale, and G. Oster
Cost of neutropenic complications of chemotherapy
Ann. Onc., March 1, 2008; 19(3): 454 - 460.
[Abstract] [Full Text] [PDF]


Home page
Ann OncolHome page
G. von Minckwitz, S. Kummel, A. du Bois, W. Eiermann, H. Eidtmann, B. Gerber, J. Hilfrich, J. Huober, S. D. Costa, C. Jackisch, et al.
Pegfilgrastim {+/-} ciprofloxacin for primary prophylaxis with TAC (docetaxel/doxorubicin/cyclophosphamide) chemotherapy for breast cancer. Results from the GEPARTRIO study
Ann. Onc., February 1, 2008; 19(2): 292 - 298.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
J. N.H. Timmer-Bonte, E. M.M. Adang, E. Termeer, J. L. Severens, and V. C.G. Tjan-Heijnen
Modeling the Cost Effectiveness of Secondary Febrile Neutropenia Prophylaxis During Standard-Dose Chemotherapy
J. Clin. Oncol., January 10, 2008; 26(2): 290 - 296.
[Abstract] [Full Text] [PDF]


Home page
The OncologistHome page
H. Ozer, B. Mirtsching, M. Rader, S. Luedke, S. J. Noga, B. Ding, and L. Dreiling
In Reply
Oncologist, December 1, 2007; 12(12): 1465 - 1466.
[Full Text] [PDF]


Home page
The Annals of PharmacotherapyHome page
J.-J. Lee, M. S. Lam, and A. Rosenberg
Role of Chemotherapy and Rituximab for Treatment of Posttransplant Lymphoproliferative Disorder in Solid Organ Transplantation
Ann. Pharmacother., October 1, 2007; 41(10): 1648 - 1659.
[Abstract] [Full Text] [PDF]


Home page
The OncologistHome page
B. H. Segal
Role of Macrophages in Host Defense Against Aspergillosis and Strategies for Immune Augmentation
Oncologist, October 1, 2007; 12(suppl_2): 7 - 13.
[Abstract] [Full Text] [PDF]


Home page
ANN INTERN MEDHome page
L. Sung, P. C. Nathan, S. M.H. Alibhai, G. A. Tomlinson, and J. Beyene
Meta-analysis: Effect of Prophylactic Hematopoietic Colony-Stimulating Factors on Mortality and Outcomes of Infection
Ann Intern Med, September 18, 2007; 147(6): 400 - 411.
[Abstract] [Full Text] [PDF]


Home page
The Annals of PharmacotherapyHome page
K. A Mergenhagen and M. T Pasko
Daptomycin Use After Vancomycin-Induced Neutropenia in a Patient with Left-Sided Endocarditis
Ann. Pharmacother., September 1, 2007; 41(9): 1531 - 1535.
[Abstract] [Full Text] [PDF]


Home page
The OncologistHome page
D. M. Courtney, A. Z. Aldeen, S. M. Gorman, J. A. Handler, S. M. Trifilio, J. P. Parada, P. R. Yarnold, and C. L. Bennett
Cancer-Associated Neutropenic Fever: Clinical Outcome and Economic Costs of Emergency Department Care
Oncologist, August 1, 2007; 12(8): 1019 - 1026.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
N. M. Kuderer, D. C. Dale, J. Crawford, and G. H. Lyman
Impact of Primary Prophylaxis With Granulocyte Colony-Stimulating Factor on Febrile Neutropenia and Mortality in Adult Cancer Patients Receiving Chemotherapy: A Systematic Review
J. Clin. Oncol., July 20, 2007; 25(21): 3158 - 3167.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
J. A. Ajani
In Reply
J. Clin. Oncol., June 10, 2007; 25(17): 2491 - 2493.
[Full Text] [PDF]


Home page
JCOHome page
S. M. Lichtman, L. Balducci, and M. Aapro
Geriatric Oncology: A Field Coming of Age
J. Clin. Oncol., May 10, 2007; 25(14): 1821 - 1823.
[Full Text] [PDF]


Home page
JCOHome page
S. M. Lichtman, H. Wildiers, E. Chatelut, C. Steer, D. Budman, V. A. Morrison, B. Tranchand, I. Shapira, and M. Aapro
International Society of Geriatric Oncology Chemotherapy Taskforce: Evaluation of Chemotherapy in Older Patients--An Analysis of the Medical Literature
J. Clin. Oncol., May 10, 2007; 25(14): 1832 - 1843.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
A. C. Hirbe, O. Uluckan, E. A. Morgan, M. C. Eagleton, J. L. Prior, D. Piwnica-Worms, K. Trinkaus, A. Apicelli, and K. Weilbaecher
Granulocyte colony-stimulating factor enhances bone tumor growth in mice in an osteoclast-dependent manner
Blood, April 15, 2007; 109(8): 3424 - 3431.
[Abstract] [Full Text] [PDF]


Home page
The OncologistHome page
H. Ozer, B. Mirtsching, M. Rader, S. Luedke, S. J. Noga, B. Ding, and L. Dreiling
Neutropenic Events in Community Practices Reduced by First and Subsequent Cycle Pegfilgrastim Use
Oncologist, April 1, 2007; 12(4): 484 - 494.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
G. Ferretti and P. Papaldo
Can the Addition of Prophylactic Filgrastim Be Considered Cost Effective in Early Breast Cancer Patients Treated With Epirubicin and Cyclophosphamide?
J. Clin. Oncol., December 10, 2006; 24(35): 5615 - 5616.
[Full Text] [PDF]


Home page
JCOHome page
A. Dekker, S. Bulley, J. Beyene, L. L. Dupuis, J. J. Doyle, and L. Sung
Meta-Analysis of Randomized Controlled Trials of Prophylactic Granulocyte Colony-Stimulating Factor and Granulocyte-Macrophage Colony-Stimulating Factor After Autologous and Allogeneic Stem Cell Transplantation
J. Clin. Oncol., November 20, 2006; 24(33): 5207 - 5215.
[Abstract] [Full Text] [PDF]


Home page
Ann OncolHome page
P. S. Hupperets and V. C. Tjan-Heijnen
Primary or secondary G-CSF prophylaxis to support TAC chemotherapy in breast cancer?
Ann. Onc., August 1, 2006; 17(8): 1181 - 1183.
[Full Text] [PDF]


Home page
JCOHome page
J. R. Adams, C. Angelotta, and C. L. Bennett
When the Risk of Febrile Neutropenia Is 20%, Prophylactic Colony-Stimulating Factor Use Is Clinically Effective, but Is It Cost-Effective?
J. Clin. Oncol., July 1, 2006; 24(19): 2975 - 2977.
[Full Text] [PDF]



About
JCO
 Editorial
Roster
 Advertising
Information
 Librarians &
Institutions
 Rights &
Permissions
 Site Map

Copyright © 2006 by the American Society of Clinical Oncology, Online ISSN: 1527-7755. Print ISSN: 0732-183X
Terms and Conditions of Use
  HighWire Press HighWire Press™ assists in the publication of JCO Online